Business Wire

CO-WESTERN-UNION

14.2.2020 06:32:04 CET | Business Wire | Press release

Share
Western Union Launches Worldwide Coronavirus Relief Drive

Today, Western Union (NYSE: WU) a leader in cross-border, cross-currency money movement and payments, and the Western Union Foundation announced a USD $1M global matching challenge to help fight COVID-19 (coronavirus) and for relief in China and other affected countries. The combined Western Union and Western Union Foundation match will be up to USD $500,000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005982/en/

The Western Union Foundation is accepting contributions from Western Union employees, Agents, customers, and the public, across the globe between now and April 14, 2020. The aid will be pledged to local and global NGOs, including Give2Asia and International Medical Corps* for ongoing relief efforts in China and other impacted nations throughout the world, including to purchase supplies, equipment and frontline medical treatment.

As of February 13, 46,997 individuals are estimated to have been infected with COVID-19, with 1,368 deaths globally (46,550 cases and 1,368 deaths in China), according to the World Health Organization .

“Western Union is a global company and we support our customers, employees and communities in times of need. The time is now for the global community to come together in support of communities affected by COVID-19,” said Western Union CEO Hikmet Ersek. “Being a responsible global company means not just serving and benefiting from an interconnected world but taking steps to care for vulnerable communities in dire times. We encourage everyone across the world including our employees, Agents and customers and partners, to step up and show their support.”

Donations towards the $1M challenge can be made via:

In addition to offering money for on-the-ground efforts to prevent and combat the spread of COVID-19, Western Union and the Western Union Foundation have launched a worldwide campaign to drive awareness and encourage donations from the public including Western Union employees, Agents, and customers.

“We are committed to helping our partner organizations fight this virus in whatever ways are most appropriate in their localities,” said Elizabeth Roscoe, Western Union Foundation Executive Director and Western Union Head of Corporate Brand & Purpose. “We understand the importance of doing our small part to bring the global community together to combat this infectious disease which can endanger everyone equally, without regard for boundaries of geography, ethnicity or social class.”

Give2Asia said it is thankful for the help and support from the global community, but more is always welcome. “We are grateful to everyone who is taking action in this time of need,” said Birger Stamperdahl, Give2Asia’s President and CEO. "Frontline health workers are risking their lives to help control the spread of the virus. Give2Asia sees a strong commitment on the part of the global community to support their work and to help families and communities hurt by the outbreak.”

WU-G

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of December 31, 2019, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 70 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .

About the Western Union Foundation

The Western Union Foundation believes that education is the surest pathway to economic opportunity. After nearly 20 years of impact, we are continuing to deliver against our mission with our Opportunity Beyond Borders commitment, to invest $15 million by 2022, with a focus on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. We also provide funding to communities in crisis through disaster relief and other humanitarian efforts, a key reason for forced migration. To date, more than $124 million has been given to fund projects and scholarships in 174 countries across the globe. The Western Union Foundation is a separate charitable corporation that is tax-exempt under 501(c)(3) of the US Internal Revenue Code, and receives support from The Western Union Company, its employees, Agents and business partners. Contributions to the Foundation are tax-deductible for US income tax purposes. To learn more, visit wu.com/foundation or follow us on Twitter @TheWUFoundation.

*The Western Union Foundation will commit 100 percent of funds raised via public donations to Give2Asia and International Medical Corps

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye